Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) have been given an average recommendation of “Buy” by the ten analysts that are presently covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $46.4286.
Several research analysts have recently weighed in on AAPG shares. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target for the company. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company.
Get Our Latest Stock Analysis on AAPG
Ascentage Pharma Group International Price Performance
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter. Equities analysts expect that Ascentage Pharma Group International will post -0.96 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of AAPG. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the second quarter valued at $391,000. XY Capital Ltd increased its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the last quarter. Finally, UBS Group AG increased its position in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.
Founded in 2008 by biotechnology entrepreneur Dr.
Read More
- Five stocks we like better than Ascentage Pharma Group International
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
